arrow
R

Rikke Olesen

Aarhus University
H指数:30
被引数:4,053

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity

TLR9激动对人类NK细胞介导的直接杀伤和抗体依赖性细胞介导的细胞毒性的影响不同

2024-06-250
OAAI
Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection

疫苗接种和感染后2年内新型冠状病毒T细胞免疫的纵向评估

2024-04-300
OAAI
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

TLR9激动剂和广泛中和抗体对HIV-1持久性的影响: TITAN 2a期随机试验

2023-09-1123
OAAI
Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity

年龄和合并症对SARS-CoV-2疫苗诱导的T细胞免疫的影响

2023-04-2420
OAAI
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity

在ART起始时给予广泛中和性anti-HIV-1抗体维持长期CD8 T细胞免疫

2022-10-2933
OAAI
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

3BNC117和romidepsin在HIV-1患者抗逆转录病毒治疗开始时的早期干预: 1b/2a期随机试验

2022-10-1752
OA
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses

SARS-CoV-2持久性与抗原特异性CD8 T细胞反应有关

2021-02-01100
OAAI
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+individuals

24周Toll样受体9激动剂治疗对HIV 1型个体的影响

AIDS
IF3.1
2019-07-0173
PREAI
TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes
2019-07-0127
OAAI
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits &ITEx Vivo&IT Lipopolysaccharide-Induced Inflammatory Responses
MSPHERE
IF3.1
2018-02-2820
OAAI
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection
2017-03-09140
OAAI
Combined eff ect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
2016-10-01157
PREAI
Broad activation of latent HIV-1 in vivo
2016-09-0872
OAAI